Evaluation of SRT candidates for six Mucopolysaccharidoses
The Sanfilippo Children’s Foundation and Cure Sanfilippo Foundation have awarded funds to Professor Andreas Schulze at The Hospital for Sick Children in Toronto. Prof. Schulze will continue his work on the development of substrate reduction therapy drugs for Sanfilippo and other similar conditions.
Sanfilippo Syndrome involves the accumulation of heparan sulphate (HS) in the body, resulting in progressive mental and physical deterioration. One therapeutic approach involves substrate reduction therapy (SRT), which aims to reduce the initial production of HS. As a result, there is less build-up over time, helping to slow disease progression and reduce symptoms.
In 2016, Prof. Andreas Schulze was awarded a translational grant co-funded by the Sanfilippo Children’s Foundation and Cure Sanfilippo Foundation (USA). For that project, Prof. Schulze performed high-throughput screening to identify potential SRT drugs for Sanfilippo and other MPS disorders involving HS accumulation. By screening over 7,100,000 compounds using computer modelling and 4,302 compounds in cells, Prof. Schulze and his team found nine potential drug candidates to further characterise, which will be the subject of this new project.
Their SRT approach involves inhibiting the enzyme NDST, which plays an important role in the production of HS. Five of the candidates that will be evaluated in this study can prevent the enzyme from being produced, and the other four stop the produced NDST enzyme from working correctly. By targeting NDST, it may be possible to reduce HS production and improve symptoms.
To build upon their previous work, the research team will continue to evaluate the SRT potential of the nine candidates, in order to select the top compounds for future preclinical animal studies. The five compounds that prevent NDST production will be tested in new cell lines, including Sanfilippo types A, B and C cells, and a neuronal-like cell model. For the four that target the NDST enzyme directly, their exact mechanism of action will be investigated. Finally, all nine compounds will be studied in Sanfilippo types A, B and C skin cells, to determine their effectiveness in reducing HS production.
“We are very grateful for the continued funding collaboration with Cure Sanfilippo Foundation for this project,” said Megan Donnell, Founder and Director of the Sanfilippo Children’s Foundation. “As supporters of this project since its inception, we are excited by how far it has come and to be able to support this next phase of the research, bringing it another step closer to clinical application.”
This sentiment is echoed by Victoria Bowring, CEO of the Sanfilippo Foundation: “It is important to celebrate the hard work of Sanfilippo researchers and continue to support this vital research. Our mission is, and always will be, to fund research with the potential to treat patients with this devastating disease.”
Professor Andreas Schulze is a biochemist and pediatrician with over 26 years of experience in the diagnosis and management of patients with inherited metabolic diseases. He is the head of Metabolic Genetics at The Hospital for Sick Children, and leads a laboratory at the hospital’s dedicated Research Institute.
Project title: Identify a novel class of substrate reduction therapy drugs for the mucopolysaccharidoses that inhibit N-deacetylase/N-sulfo-transferase (NDST)
Chief investigator: Prof. Andreas Schulze
Amount: $62,581, with Cure Sanfilippo Foundation contributing a further $62,581
Duration: 1 year
Location: The Hospital for Sick Children, Toronto
Start date: December 2020